Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.

ABSTRACT:

Importance

The Breast Cancer Index (BCI) previously identified premenopausal patients with tumors in which the ratio of expression of HOXB13 relative to IL17BR (hereafter, BCI [H/I]-low tumors) as likely to derive greatest benefit from ovarian function suppression (OFS)-containing adjuvant therapy in the Suppression of Ovarian Function Trial (SOFT) trial.

Objectives

To assess BCI as a predictive biomarker of benefit from exemestane plus OFS vs tamoxifen plus OFS and to validate BCI as a prognostic biomarker for premenopausal patients.

Design, setting, and participants

This prognostic study used a prospective-retrospective translational design within the Tamoxifen and Exemestane (TEXT) and SOFT trials (enrolled November 2003 to April 2011). Blinded BCI testing in all a

SUBMITTER: O'Regan RM 

PROVIDER: S-EPMC12584034 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature